0 13 eps expected for psivida corp psdv

$-0.13 EPS Expected for pSivida Corp. (PSDV)

April 2, 2018 – By Migdalia James

pSivida Corp. (NASDAQ:PSDV) LogoInvestors sentiment increased to 0.92 in 2017 Q4. Its up 0.30, from 0.62 in 2017Q3. It improved, as 7 investors sold pSivida Corp. shares while 6 reduced holdings. 5 funds opened positions while 7 raised stakes. 4.79 million shares or 10.05% more from 4.35 million shares in 2017Q3 were reported.

10,000 were reported by United Capital Advisers Limited Liability Corporation. Essex Management Ltd Llc stated it has 160,612 shares. Citadel Advsrs has invested 0% in pSivida Corp. (NASDAQ:PSDV). Bankshares Of Ny Mellon stated it has 0% of its portfolio in pSivida Corp. (NASDAQ:PSDV). 64,900 were reported by California Employees Retirement Sys. Royal Natl Bank Of Canada holds 0% or 528 shares. Morgan Stanley reported 274,333 shares. Telemus Lc accumulated 1,400 shares. Renaissance Technology Ltd Liability Corporation reported 0% of its portfolio in pSivida Corp. (NASDAQ:PSDV). Matrix Asset Advsr Incorporated New York has 28,500 shares for 0% of their portfolio. 62,011 were reported by Northern Tru. Paragon Management Limited has 22,750 shares. Vanguard Gp stated it has 0% in pSivida Corp. (NASDAQ:PSDV). Atlantic Trust Group Inc Limited Company invested 0% of its portfolio in pSivida Corp. (NASDAQ:PSDV). 4,068 were accumulated by Gp One Trading L P.

Analysts expect pSivida Corp. (NASDAQ:PSDV) to report $-0.13 EPS on May, 3.They anticipate $0.02 EPS change or 13.33 % from last quarter’s $-0.15 EPS. After having $-0.13 EPS previously, pSivida Corp.’s analysts see 0.00 % EPS growth. The stock increased 14.02% or $0.15 during the last trading session, reaching $1.22. About 1.18 million shares traded or 214.32% up from the average. pSivida Corp. (NASDAQ:PSDV) has declined 35.47% since April 2, 2017 and is downtrending. It has underperformed by 47.02% the S&P500.

pSivida Corp. (NASDAQ:PSDV) Ratings Coverage

Among 3 analysts covering pSivida (NASDAQ:PSDV), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. pSivida had 9 analyst reports since October 11, 2017 according to SRatingsIntel. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, November 8 report. The firm earned “Buy” rating on Thursday, February 8 by H.C. Wainwright. H.C. Wainwright maintained pSivida Corp. (NASDAQ:PSDV) rating on Wednesday, October 11. H.C. Wainwright has “Buy” rating and $5.0 target. The stock has “Buy” rating by H.C. Wainwright on Friday, December 15. FBR Capital initiated pSivida Corp. (NASDAQ:PSDV) on Monday, February 5 with “Buy” rating. The stock of pSivida Corp. (NASDAQ:PSDV) has “Buy” rating given on Tuesday, January 9 by H.C. Wainwright. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, March 20.

pSivida Corp. develops sustained-release drug-delivery products for the treatment of chronic eye diseases in the United States and the United Kingdom. The company has market cap of $55.21 million. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior segment uveitis. It currently has negative earnings. The firm is also developing Durasert, an injectable, sustained-release micro-insert, which is in Phase III clinical trials for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

pSivida Corp. (NASDAQ:PSDV) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Back To Top